P0965: Sequencing Therapy for Optimal Response in Mirikizumab (STORM) StudyECCO'25Year: 2025
Authors: Kubesch, A.(1)*;Lande, R.(1);Farrag, K.(1);Dienethal, A.(1);Sprinzl, K.(1);Zeuzem, S.(1);Blumenstein, I.(1);
(1)Goethe University- University Hospital, Department of Internal Medicine I, Frankfurt, Germany;
P0966: Fecal calprotectin in Small Bowel Crohn's Disease: is it a reliable tool?ECCO'25Year: 2025
Authors: Souto, M.(1,2,3)*;Ferreira, A.I.(1,2,3);Gonçalves, J.(1,2,3);Macedo Silva, V.(1,2,3);Arieira, C.(1,2,3);Dias de Castro, F.(1,2,3);Leite, S.(1,2,3);Cotter, J.(1,2,3);
(1)ULS Alto Ave, Gastroenterology, Guimarães, Portugal;(2)ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal;(3)Life and Health Sciences Research Institute ICVS, School of Medicine- University of Minho, Braga, Portugal;
P0967: The role of bound anti-drug antibodies to infliximab in predicting future immunogenic failure when de-escalating from combination therapy with an immunomodulator to anti-TNF monotherapy (RAPID-IM Study)ECCO'25Year: 2025
Authors: Cameron, K.(1)*;Sam, M.(2);Theena, N.(3);Gu, B.(4);Arzivian, A.(5);Skinner, T.(5);Shelton, E.(3);Connor, S.J.(4);Toong, C.(2);Gibson, P.R.(1);Gibson, D.J.(1);Sparrow, M.P.(1);Ward, M.G.(1);
(1)Alfred Health / Monash University, Gastroenterology, Melbourne, Australia;(2)NSW Health Pathology- Immunology Laboratory- Liverpool Hospital / Ingham Institute of Applied Medical Research, Pathology, Sydney, Australia;(3)Monash Health, Gastroenterology, Melbourne, Australia;(4)Liverpool Hospital, Gastroenterology, Sydney, Australia;(5)St Vincent's Hospital Sydney, Gastroenterology, Sydney, Australia;
P0968: Comparison of two oral iron formulations for iron deficiency and iron deficiency anemia in inflamatory bowel disease: a multicentric prospective studyECCO'25Year: 2025
Authors: Guimaraes, A.(1)*;Leal, T.(1);Carvalho, T.(1);Mendes, S.(1);Gonçalves, A.(2);Leal, C.(2);Santos, A.(2);Soares, J.(1);Arroja, B.(1);Rebelo, A.(1);Damasceno, J.(1);Neves, J.(1);Gonçalves, B.(1);Rodrigues, Â.(1);Vasconcelos, H.(1);Gonçalves, R.(1);
(1)Unidade Local de Saúde de Braga, Gastrenterology, Braga, Portugal;(2)Unidade Local de Saúde de Leiria, Gastrenterology, Leiria, Portugal;
P0969: Treat to Target strategy in IBD: A real world multicentre experienceECCO'25Year: 2025
Authors: Tan, Y.Y.(1);Tey, T.T.(2);Thia, T.J.K.(3);Yan, Z.H.(2);Qiu, T.Y.(1)*;Leong, W.H.J.(1);Chowdhury, S.(1);Liew, I.Y.(4);Lin, H.(4);Tan, T.K.M.(1);Lim, C.T.T.(1);Tay, S.W.(1);Salazar, E.(1);
(1)Singapore General Hospital, Gastroenterology and Hepatology, Singapore, Singapore;(2)Sengkang General Hospital, Gastroenterology and Hepatology, Singapore, Singapore;(3)Mount Elizabeth Hospital, Gastroenterology and Hepatology, Singapore, Singapore;(4)Tan Tock Seng General Hospital, Gastroenterology and Hepatology, Singapore, Singapore;
P0970: Associations between diet, faecal and flatulence odour perception and disease activity in patients with inflammatory bowel disease and healthy controlsECCO'25Year: 2025
Authors: Pueschel, L.(1);Nothacker, S.(2);Kuhn, L.(1);Wedemeyer, H.(1);Lenzen, H.(1,3);Wiestler, M.(1)*;
(1)Hannover Medical School, Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Hannover, Germany;(2)Hannover Medical School, School for Dietitians, Hannover, Germany;(3)Academic Teaching Hospital Braunschweig, Gastroenterology- Hepatology- Interventional Endoscopy and Diabetology, Braunschweig, Germany;
P0971: Effectiveness of Vedolizumab in Bio-Naïve Chinese Patients with Crohn’s Disease: A Subgroup Analysis of Second Interim Analysis of the VALUE StudyECCO'25Year: 2025
Authors: Guo, H.(1);Shen, H.(2);Jiang, Q.(3);Xu, X.(4);Qian, X.(5);Zhou, F.(6);Chen, M.(7)*;
(1)Chongqing General Hospital, Gastroenterology Department, Chongqing, China;(2)Affiliated Hospital of Nanjing University of Chinese Medicine, Gastroenterology Department, Nanjing, China;(3)The First Affiliated Hospital of Ningbo University, Gastroenterology Department, Ningbo, China;(4)The First Affiliated Hospital of China Medical University, Gastroenterology Department, Shenyang, China;(5)Takeda China International Trade Co.- Ltd- Shanghai- China- 200127, China Medical Team, Nanjing, China;(6)Takeda China International Trade Co.- Ltd., China Medical Team, Shanghai, China;(7)The First Affiliated Hospital- Sun Yat-Sen University, Gastroenterology Department, Guangzhou, China;
P0972: Higher vedolizumab clearance associates with poor therapeutic outcomes during maintenance therapy of vedolizumab in Crohn's diseaseECCO'25Year: 2025
Authors: AnjieMD, S.(1)*;D'Haens, G.R.A.M.(1);Baert, F.(2);Bossuyt, P.(3);Hoentjen, F.(4);Clasquin, E.(1);Molnar, T.(5);Lowenberg, M.(1);Vermeire, S.(6);Panetta, J.C.(7);Dervieux, T.(8);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Az Delta, Department of Gastroenterology and Hepatology, Roeselare, Belgium;(3)Imelda General Hospital, Department of Gastroenterology and Hepatology, Bonheiden, Belgium;(4)University of Alberta, Department of Gastroenterology and Hepatology, Edmonton, Canada;(5)University of Szeged, Department of Internal Medicine, Szeged, Hungary;(6)University Hospital Leuven, Department of Gastroenterology, Leuven, Belgium;(7)St Jude Children’s Research Hospital, Department of Pharmaceutical Sciences, Memphis, United States;(8)Prometheus Laboratories, Research and Development, San Diego, United States;
P0973: Early infliximab use is associated with less disease progression in luminal Crohn's disease: a real-world tertiary centre experienceECCO'25Year: 2025
Authors: Gordon, H.(1)*;Pakpoor, J.(1);Radia, C.(2);FurtadoOMahony, L.(1);Sanford, J.(1);Azzu, H.(1);Valentine, C.(1);Al-Allawee, M.(1);Gupta, T.(1);Brain, O.(1);
(1)John Radcliffe Hospital- Oxford University Hospitals NHS Trust, Translational Gastroenterology Unit, Oxford, United Kingdom;(2)Kings College Hospital NHS Foundation Trust, Gastroenterology, Oxford, United Kingdom;
Noor NM et al. PROFILE. Gastro Lancet Hep 2024
P0974: Risk factors for anti-TNFα induced paradoxical psoriasis in Inflammatory Bowel Disease and association with an IL-23 receptor polymorphism: A retrospective studyECCO'25Year: 2025
Authors: Natt, N.(1)*;Gindi, M.(2);Gregor, J.(1);Ponich, T.(1);Chande, N.(1);Kim, R.(3);Wilson, A.(4);
(1)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(2)Western University, Department of Medicine, London, Canada;(3)Western University, Department of Medicine- Department of Physiology and Pharmacology- Division of Clinical Pharmacology & Toxicology, London, Canada;(4)Western University, Department of Medicine- Department of Physiology and Pharmacology- Division of Clinical Pharmacology & Toxicology- Division of Gastroenterology, London, Canada;
P0975: Cost-effectiveness analysis of anti-TNF treatment from diagnosis for patients with moderate and severe Crohn’s disease: an analysis using data from the PROFILE trialECCO'25Year: 2025
Authors: Noor, N.(1)*;Davies, N.(2);Tahir, W.(2);Bond, S.(3);Dowling, F.(3);Brezina, B.(4);Patel, K.(5);Lee, J.(6);Lyons, P.(1);McKinney, E.(1);Smith, K.(7);Buchanan, V.(2);Parkes, M.(4);
(1)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(2)Cogentia Healthcare Consulting, Health Technology Assessment, Cambridge, United Kingdom;(3)Cambridge University Hospitals NHS Foundation Trust, Cambridge Clinical Trials Unit, Cambridge, United Kingdom;(4)Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom;(5)St George’s University Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(6)The Francis Crick Institute, Genetic Mechanisms of Disease Laboratory, London, United Kingdom;(7)University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; PROFILE Study Group
Noor NM et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427.
P0976: Guselkumab efficacy and safety in East Asian participants with moderate to severely active Crohn’s disease: Subgroup analysis of the GALAXI 2 & 3 Phase 3 studiesECCO'25Year: 2025
Authors: Nakase, H.(1);Chen, B.(2);Cao, Q.(3);Matsuoka, K.(4);Hisamatsu, T.(5);Park, D.I.(6);Wahking, B.(7);Yiu, W.C.(8);Zhuo, J.(9);Chen, M.(2)*;
(1)Sapporo Medical University, School of Medicine, Sapporo, Japan;(2)The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;(3)Sir Run Run Shaw Hospital- Zhejiang University, School of Medicine, Hangzhou, China;(4)Toho University, Sakura Medical Center, Chiba, Japan;(5)Kyorin University, School of Medicine, Tokyo, Japan;(6)Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea- Republic Of;(7)Janssen Asia Pacific, Medical Affairs, Singapore, Singapore;(8)Janssen Research & Development- LLC, Immunology, Spring House, United States;(9)Janssen China R&D, Statistics, Shanghai, China;
1. Panaccione R, Danese S, Feagan B, et al. Gastroenterology. 2024;166(5 Suppl):1057b.
P0977: Health-Related Physical Fitness and Its Association with Disease- and Treatment-related Characteristics in Patients with Inflammatory Bowel Disease Versus Healthy ControlsECCO'25Year: 2025
Authors: Demers, K.(1,2,3,4)*;van den Bergh, N.(4);Bongers, B.C.(2,5);van Kuijk, S.M.J.(6);Mujagic, Z.(3,4);Jonkers, D.M.A.E.(3);Pierik, M.J.(3,4);Stassen, L.P.S.(1,2);
(1)Maastricht University Medical Center +, Department of Surgery, Maastricht, The Netherlands;(2)Institute of Nutrition and Translational Research in Metabolism NUTRIM, Department of Surgery, Maastricht, The Netherlands;(3)Institute of Nutrition and Translational Research in Metabolism NUTRIM, Department of Gastroenterology-Hepatology, Maastricht, The Netherlands;(4)Maastricht University Medical Center +, Department of Gastroenterology-Hepatology, Maastricht, The Netherlands;(5)Institute of Nutrition and Translational Research in Metabolism NUTRIM, Department of Nutrition and Movement Sciences, Maastricht, The Netherlands;(6)Maastricht University Medical Center +, Department of Clinical Epidemiology and Medical Technology Assessment KEMTA, Maastricht, The Netherlands;
1. Demers K, Bongers BC, van Kuijk SMJ, Plasqui G, Jonkers DMAE, Pierik MJ, Stassen LPS. Criterion Validity of Screening Tools and Field-Based Tests for Health-Related Physical Fitness in Inflammatory Bowel Disease. Dig Dis Sci. 2024 Oct 19. doi: 10.1007/s10620-024-08682-5. Epub ahead of print. PMID: 39425857.
P0978: Effectiveness of risankizumab in moderate-to-severe Crohn’s Disease: A Canadian multicentric real-world studyECCO'25Year: 2025
Authors: Zoughlami, A.(1)*;Abbas, A.(1);Almushir, S.(1);Zeghal, M.(2);Khan, N.S.(3);Milgrom, R.(4);Daher, S.(5);McCurdy, J.D.(2);Narula, N.(3);Rosenfeld, G.(5);Silverberg, M.S.(4);Lakatos, P.L.(1);Bessissow, T.(1);
(1)McGill University, Division of Gastroenterology & Hepatology, Montreal, Canada;(2)University of Ottawa, Division of Gastroenterology and Hepatology, Ottawa, Canada;(3)McMaster University - Hamilton Health Sciences, Department of Gastroenterology, Hamilton, Canada;(4)Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases, Toronto, Canada;(5)IBD Centre of BC, IBD Centre of BC, Vancouver, Canada;
P0979: Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn’s disease: A retrospective, mul-ticenter studyECCO'25Year: 2025
Authors: Farkas, B.(1)*;Bessissow, T.(2);Limdi, J.K.(3);Sethi-Arora, K.(3);Kagramanova, A.(4);Knyazev, O.(4);Bezzio, C.(5);Armuzzi, A.(5);Lukas, M.(6);Michalopoulos, G.(7);Chaskova, E.(8);Savarino, E.V.(9);Castiglione, F.(10);Rispo, A.(10);Schäfer, E.(11);Saibeni, S.(12);Filip, R.(13);Attauabi, M.(14);Fousekis, F.S.(15);Bacsur, P.(1);Resál, T.(16);Bálint, A.(1);Ivány, E.(1);Szepes, Z.(1);Bősze, Z.(1);Fábián, A.(1);Bor, R.(1);Farkas, K.(1);Lakatos, P.L.(2);Molnár, T.(1);
(1)University of Szeged, Center for Gastroenterology, Szeged, Hungary;(2)McGill University Health Centre, Division of Gastroenterology, Montreal, Canada;(3)Northern Care Alliance NHS Foundation Trust, IBD Unit, Manchester, United Kingdom;(4)Moscow Clinical Scientific Center named after A. S. Loginov, Gastroenterology, Moscow, Russian Federation;(5)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(6)Clinical and Research Centre for Inflammatory Bowel Diseases, IBD Unit, Prague, Czech Republic;(7)General Hospital of Athens "G. Gennimatas", Gastroenterology, Athens, Greece;(8)Irkutsk Regional Hospital, Department of Coloproctology, Irkutsk, Russian Federation;(9)Azienda Ospedale Università of Padua, Gastroenterology Unit, Padua, Italy;(10)University of Naples Federico II, Gastroenterology Department of Clinical Medicine and Surgery, Naples, Italy;(11)Hungarian Defence Forces Military Hospital, Department of Gastroenterology, Budapest, Hungary;(12)Rho Hospital- ASST Rhodense, Gastroenterology Unit, Milan, Italy;(13)Clinical Hospital 2, Department of Gastroenterology with IBD Unit, Rzeszów, Poland;(14)Copenhagen University Hospital - Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(15)University Hospital of Ioannina, Division of Gastroenterology, Division of Gastroenterology, Greece;(16)HCEMM-USZ, Translational Colorectal Research Group, Szeged, Hungary;
P0980: Virtual chromoendoscopy is comparable to dye spray chromoendoscopy for IBD surveillance: a single centre retrospective study.ECCO'25Year: 2025
Authors: Gallagher, R.(1)*;Brown, R.(2);Woodrow, S.(2);Shalabi, A.(2);Shepherd, T.(2);
(1)NHS Frimley Health Foundation Trust, Gastroenterology, Camberley, United Kingdom;(2)Frimley Health NHS Trust, Gastroenterology, Camberley, United Kingdom;
1. Dyson, J. K. & Rutter, M. D. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J. Gastroenterol. 18 29, 3839–3848 (2012)
2. Bye WA, Ma C, Nguyen TM, Parker CE, Jairath V, East JE. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. Am J Gastroenterol. 2018;113(12):1801-1809. doi:10.1038/s41395-018-0354-7
3. Bisschops Raf et al. Advanced imaging for detection and differentiation of colorectal neoplasia: ESGE Guideline – Update 2019 . Endoscopy 2019; 51
P0981: Comparative efficacy of standard vs enhanced dose treatment with infliximab in the management of acute severe ulcerative colitis: a single centre retrospective cohort study.ECCO'25Year: 2025
Authors: Saeed, M.H.(1)*;Ismail, A.(1);Thiruselvan, K.(1);Umar, N.(1);Slater, J.(1);King, D.(1);De Silva, S.(1);
(1)The Dudley Group NHS Foundation Trust, Gastroenterology, Dudley, United Kingdom;
1. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Choy, Matthew C et al. The Lancet Gastroenterology & Hepatology, Volume 9, Issue 11, 981 - 996
P0982: Efficacy of upadacitinib in patients with Crohn’s disease and an ostomy: A matched retrospective real-world cohort analysisECCO'25Year: 2025
Authors: Aldiabat, M.(1);Yarur, A.(2);Peyrin-Biroulet, L.(3);Loftus- Jr., E.V.(4);Colombel, J.F.(5);Deepak, P.(6)*;
(1)Washington University in St. Louis School of Medicine, Gastroenterology, St. Louis, United States;(2)Cedars Sinai Medical Center, Gastroenterology, Los Angeles, United States;(3)Nancy University Hospital, Inflammatory Bowel Disease IBD Unit, Vandoeuvre-les-Nancy, France;(4)College of Medicine Mayo Clinic, Gastroenterology, Rochester, United States;(5)Icahn School of Medicine at Mt. Sinai, Gastroenterology, New York City, United States;(6)Washington University School of Medicine in St. Louis, Gastroenterology, Saint Louis, United States;
P0983: Addition of fibre to exclusive enteral nutrition (EEN) improves colonic effects and symptoms without compromising the benefits on small bowel paracellular permeability in healthy humansECCO'25Year: 2025
Authors: Melton, S.(1,2)*;Gibson, P.(1);Taylor, K.(1);Halmos, E.(1);
(1)Monash University, Gastroenterology, Melbourne, Australia;(2)Alfred Health, Nutrition, Melbourne, Australia;
P0984: Treatment with allopurinol and low-dose azathioprine during pregnancy in patients with Inflammatory Bowel Disease. A Danish single center experience.ECCO'25Year: 2025
Authors: Sivananthan, K.(1,2)*;Wildt, S.(1,2);Kiszka-Kanowitz, M.(1,2);Pedersen, G.(1,2);Vind, I.(1,2,3);Nordgaard-Lassen, I.(1,2);Munk Petersen, A.(1,2,3);Burisch, J.(1,2,3);Kristensen, H.(1,2);Theede, K.(1,2);
(1)Copenhagen University Hospital- Amager and Hvidovre- Hvidovre, Gastro Unit- Medical section, Copenhagen, Denmark;(2)Copenhagen University Hospital- Amager and Hvidovre- Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults-, Copenhagen, Denmark;(3)University of Copenhagen, Department of Clinical Medicine- Faculty of Health and Medical Sciences, Copenhagen, Denmark;
